Board Meeting Details

The meeting commenced at 05:30 PM and concluded at 06:40 PM on 26th May 2026.

Key Decisions and Approvals

1. Financial Results Approval

The Board approved the Standalone Audited Financial Results for the fourth quarter and year ended 31st March 2026 along with Reports of Auditor thereon.

2. Dividend Declaration

The Board of Directors does not propose any dividend for the Financial Year 2025-26.

3. Auditor Appointments

  • Re-Appointment of M/s B. K. Khare & Co., Chartered Accountants (Firm Registration No. 105102W) as Tax Auditors for FY 2026-27 (for tax audit of FY 2025-26)
  • Re-Appointment of M/s S. R. Rege & Co., Chartered Accountants (Firm Registration No. 108813W) as Internal Auditors for FY 2026-27

4. CSR Policy

Approved the Corporate Social Responsibility (CSR) Policy in accordance with Section 135 of the Companies Act, 2013. The policy is available on the company website.

5. CSR Implementation Authority

Authorized Managing Director Mr. Adi F Madan to design, plan, implement, and monitor CSR initiatives with responsibility for execution, periodic monitoring, and reporting to the Board.

6. Withdrawal of UAE Subsidiary Proposal

Rescinded the earlier approval (dated 11th December 2025) to incorporate a Wholly Owned Subsidiary in UAE with proposed name BRHAM HOLDING FZ-LLC due to evolving strategic considerations. All previously disclosed information regarding this proposed subsidiary stands withdrawn.

Financial Results for Year Ended 31st March 2026

Income Statement Highlights (₹ in lakh)

  • Total Income: ₹3,307.16
  • Revenue from Operations: ₹2,679.21
  • Other Income: ₹627.95
  • Total Expenses: ₹924.60
  • Cost of materials consumed: ₹927.56
  • Changes in inventories: ₹134.14
  • Employee benefits expense: ₹597.56
  • Finance Costs: ₹5.27
  • Depreciation expenses: ₹51.94
  • Other expenses: ₹2.10
  • Profit before tax: ₹2,641.07
  • Tax Expenses: ₹666.09
  • Current Tax: ₹166.50
  • Deferred Tax: ₹3.62
  • Excess provision for tax relating to prior years: ₹2.10
  • Profit after tax: ₹493.87
  • Total Comprehensive Income: ₹503.81
  • Earnings per share (₹10 each): ₹3.75 (Basic and Diluted)

Balance Sheet Position as at 31st March 2026 (₹ in lakh)

  • Total Assets: ₹13,467.45
  • Non-current Assets: ₹450.80
  • Property, Plant and Equipment: ₹339.44
  • Financial Assets: ₹50.57
  • Deferred Tax Assets: ₹43.44
  • Other non-current assets: ₹17.35
  • Current Assets: ₹13,016.65
  • Inventories: ₹865.40
  • Trade receivables: ₹391.73
  • Cash and cash equivalents: ₹5,780.89
  • Bank Balances other than Cash: ₹5,671.72
  • Loans: ₹6.04
  • Other financial assets: ₹16.60
  • Other current assets: ₹284.27
  • Equity: ₹13,073.91
  • Equity Share capital: ₹1,452.33
  • Other Equity: ₹11,621.58
  • Liabilities: ₹393.54
  • Non-current Liabilities: ₹21.86
  • Current Liabilities: ₹371.68

Cash Flow Statement for Year Ended 31st March 2026 (₹ in lakh)

  • Net Cash from Operating Activities: ₹254.09
  • Net Cash used in Investing Activities: ₹(4,679.71)
  • Net Cash from Financing Activities: ₹9,973.64
  • Net increase in cash: ₹5,548.02
  • Closing Cash Balance: ₹5,780.89

Additional Notes from Financial Results

Preferential Allotment Details

The Board approved allotment of 95,99,999 Equity Shares (face value ₹10) at ₹104 per share (premium ₹94) to Mr. Bhavook Chandraprakash Tripathi.

  • SEBI Observation Letter received: 28th March 2025
  • Allotment completed: 23rd May 2025
  • Paid-up capital increased from ₹4,92,33,400 (49,23,340 shares) to ₹14,52,33,390 (1,45,23,339 shares)
  • Listing approval received: 27th March 2026
  • Trading approval received: 9th April 2026
  • Preferential allotment funds remain unutilized as of reporting date

Business Segment

The principal business is manufacturing socks, with only one primary reportable business segment as per IND AS 108.

Audit Opinion

Statutory Auditors M/s B. K. Khare & Co. issued an unmodified opinion on the financial results, confirming true and fair view in accordance with Indian Accounting Standards and SEBI Listing Regulations.